The company reported a net loss of $372.2 million for the full year 2024, although this was an improvement from the previous year.
There are challenges in scaling up ATCs, with only 13% of them having infused more than 10 patients, indicating room for growth but also current limitations.
The company faces competition from potential new entrants in the market, which could impact their market share.
Manufacturing and operational costs remain high, with cost of sales for the full year 2024 at $124 million.
There is uncertainty regarding the timing and success of future regulatory approvals and market expansions, which could affect revenue projections.
https://finance.yahoo.com/news/iovance-biotherapeutics-inc-iova-q4-073751183.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.